Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
ARCH Venture Management, LLC (CIK 1274403) reported $677.1M across 9 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: MAZE ($123.0M, 18.16%), RAPP ($116.7M, 17.23%), VIR ($115.7M, 17.09%), ERAS ($114.7M, 16.95%), BEAM ($108.2M, 15.98%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MAZE | MAZE THERAPEUTICS INC | $123.0M | 18.16% | 4.1M | Hold |
| 2 | RAPP | RAPPORT THERAPEUTICS INC | $116.7M | 17.23% | 3.7M | Hold |
| 3 | VIR | VIR BIOTECHNOLOGY INC | $115.7M | 17.09% | 12.9M | Hold |
| 4 | ERAS | ERASCA INC | $114.7M | 16.95% | 7.1M | Trimmed |
| 5 | BEAM | BEAM THERAPEUTICS INC | $108.2M | 15.98% | 4.5M | Hold |
| 6 | LYEL | LYELL IMMUNOPHARMA INC | $65.1M | 9.62% | 3.2M | Added |
| 7 | GENERATE BIOMEDICINES INC | $24.3M | 3.59% | 1.9M | New | |
| 8 | TXG | 10X GENOMICS INC | $4.6M | 0.68% | 217,834 | Trimmed |
| 9 | GOSS | GOSSAMER BIO INC | $2.6M | 0.39% | 8.1M | Hold |
| 10 | QTTB | Q32 BIO INC | $2.1M | 0.30% | 320,482 | Hold |
Source: SEC Form 13F filings · as of 2026-03-31